Transkutaninė blauzdinio nervo stimuliacija – efektyvus lėtinio vidurių užkietėjimo gydymo metodas by Stundienė, Ieva et al.
Good results with transcutaneous tibial 
nerve stimulation for advanced chronic  
constipation treatment
Transkutaninė blauzdinio nervo stimuliacija – efektyvus lėtinio vidurių 
užkietėjimo gydymo metodas
Ieva Stundienė1, Paulius Žeromskas1, Johann Pfeifer2, Jonas Valantinas1
1 Clinic of Gastroenterology, Nephrourology and Surgery, Vilnius University, Santariškių Str. 2, LT-08661 Vilnius, 
Lithuania
2 Department of General Surgery, Medical University of Graz, Auenbruggerplatz 29, Graz, A-8036 Austria
 E-mail: ieva.stundiene@santa.lt
1 Vilniaus universiteto Gastroenterologijos, nefrourologijos ir chirurgijos klinika, Santariškių g. 2, LT-08661 Vilnius
2 Graco medicinos universiteto Bendrosios chirurgijos skyrius, Auenbruggerplatz 29, Graz, A-8036, Austrija
 El. paštas: ieva.stundiene@santa.lt
Background
Chronic constipation is a common complaint with a big impact on the quality of life, which may be difficult to treat. The aim of 
this prospective pilot study was to assess the efficiency of transcutaneous posterior tibial nerve stimulation in the treatment 
of constipation in the medium term and to investigate the potential predictors of treatment success. 
Materials and methods
Forty nine patients with constipation resistant to maximal conservative therapy were treated by transcutaneous posterior 
tibial nerve stimulation twice a week for six weeks. If the treatment was successful, patients were proposed to continue the 
treatment for six months. The Knowles–Eccersley–Scott Symptom Score, the number of the bowel movements per two weeks 
and the Gastrointestinal Quality of Life index were evaluated pre- and post-treatment. The evaluation of constipation was 
performed at the baseline and after six weeks. 
Results
The effect was seen in 53.1% of patients. The mean Knowles–Eccersley–Scott Symptom Score improved significantly (from 
20.88 ± 5.19 to 15.61 ± 7.19, p < 0.001) after six weeks. The two-week stool frequency increased from the mean of 4.65 ± 
2.48 pre-treatment to 7.47 ± 3.51 post-treatment (p < 0.001). The use of laxatives decreased (p < 0.001). The Gastrointestinal 
Quality of Life index improved in all subscales (p < 0.05). The therapy was well tolerated, and no participant experienced any 
adverse event. No potential predictors of treatment success were found.
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Conclusions
Transcutaneous posterior tibial nerve stimulation may be a new safe therapeutic option in patients with constipation, who 
have failed to respond to the maximal conservative treatment. 
Key words: transcutaneous electric nerve stimulation, constipation, tibial nerve
Įvadas
Lėtinis vidurių užkietėjimas – dažnas virškinimo trakto sutrikimas, kuris labai blogina gyvenimo kokybę ir paprastai yra sunkiai 
gydomas. Šio perspektyviojo klinikinio tyrimo tikslas – įvertinti transkutaninės blauzdinio nervo stimuliacijos efektyvumą 
gydant lėtinį vidurių užkietėjimą ir nustatyti sėkmingo gydymo veiksnius. 
Tyrimo medžiaga ir metodai
Transkutaninė blauzdinio nervo stimuliacija buvo atlikta 49 lėtiniu vidurių užkietėjimu sergantiems pacientams, kuriems 
maksimalus konservatyvus gydymas buvo neveiksmingas. Stimuliacija buvo atliekama du kartus per savaitę šešias savaites. 
Vertinti Knowles–Eccersley–Scott vidurių užkietėjimo klausimyno balų, tuštinimosi dažnio ir gastrointestinio gyvenimo koky-
bės klausimyno balų pokyčiai prieš gydymą ir po jo. 
Rezultatai
Poveikis gautas 53,1 % pacientų. Po 6 gydymo savaičių Knowles–Eccersley–Scott klausimyno balų vidurkis sumažėjo nuo 
20,88 ± 5,19 iki 15,61 ± 7,19 (p < 0,001). Tuštinimosi dažnis per dvi savaites padidėjo nuo 4,65 ± 2,48 iki 7,47 ± 3,51 (p < 0,001). 
Sumažėjo vartojamų laisvinamųjų medikamentų kiekis (p < 0,001). Nustatytas akivaizdus teigiamas pokytis pagal visas gas-
trointestinio gyvenimo kokybės klausimyno skales (p < 0,05). Pacientai gerai toleravo gydymą ir nepasitaikė jokių šalutinių 
poveikių. Galimų sėkmingo gydymo prediktorių nenustatyta.
Išvada
Transkutaninė blauzdinio nervo stimuliacija yra naujas, saugus gydymo metodas, kuris gali būti taikomas vaistams atspariam 
lėtiniam vidurių užkietėjimui gydyti. 
Reikšminiai žodžiai: transkutaninė elektrinė nervo stimuliacija, vidurių užkietėjimas, blauzdinis nervas
tely invasive therapy with a significant risk of compli-
cations and a high financial cost [7, 12]. 
An alternative to SNS is tibial nerve stimulation, a 
peripheral neuromodulation of the sacral nerve plexus, 
which is used to treat urinary incontinence and the ove-
ractive bladder syndrome as well as fecal incontinence 
[13–15]. Various stimulation parameters and regimens 
through percutaneous (using needle electrodes) or 
transcutaneous (adhesive electrodes) methods are used. 
Tibial nerve stimulation is a simple, well-tolerated and 
low-cost technique. There is a limited evidence that 
percutaneous (PTNS) and transcutaneous posterior ti-
bial nerve stimulation (TTNS) are beneficial in treating 
slow transit constipation [8, 16]. To our knowledge, 
there are no data about the effect of TTNS or PTNS on 
obstructive defecation and normal transit constipation. 
This prospective pilot study aimed to evaluate the 
efcacy of transcutaneous tibial nerve stimulation for 
constipation in the medium term and to investigate the 
potential predictors of treatment success. 
Introduction
Constipation is the most common digestive complaint 
affecting around 14% of adults worldwide [1, 2]. Chro-
nic severe constipation has a significant, even debilita-
ting, effect on the quality of life [1–4]. The disease is 
frequently multifactorial and can result from systemic 
or neurogenic disorders or medications, but the majo-
rity of patients suffer from idiopathic constipation [5]. 
A number of patients remain resistant to the maximal 
conservative therapy. However, the surgical treatment of 
constipation carries a significant risk of complications 
[6, 7]. Even if it often improves defecation frequency, 
symptoms of abdominal pain persist in the majority of 
patients, reflecting the panenteric motility disorder [8]. 
Currently, the modulation of the sacral plexus with 
sacral nerve stimulation (SNS) is widely used in clinical 
practice for the treatment of urinary incontinence and 
retention, fecal incontinence and constipation (slow 
transit constipation as well as obstructive defecation) 
with reported good results [5, 9–11]. SNS is a modera-
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Materials and methods
Study population
From November 2011 to June 2013, 49 patients with 
constipation, who were referred to a specialized centre 
and satisfied the inclusion and exclusion criteria, were 
prospectively enrolled in the consecutive cohort study. 
Constipation was defined as fewer than two bowel 
movements per week and/or straining or incomplete 
evacuation in more than 25% of all visits to the toilet 
[11]. Inclusion criteria were age over 18 years, symptoms 
present for a minimum of one year, psychological stabi-
lity, failed conservative therapy, and an adequate motor 
and/or sensory response to the treatment. Exclusion 
criteria were any organic pathology causing constipa-
tion, previous large-bowel surgery, inflammatory bowel 
disease, erratic bowel habit (alternating constipation and 
diarrhea, or the irritable bowel syndrome), congenital 
anorectal malformations, stoma in situ, neurologic 
diseases causing constipation, a significant psychologi-
cal element to the patient’s symptoms (as judged by a 
physician), pregnancy or intention to become pregnant, 
implanted pacemaker or defibrillator, diabetes mellitus, 
severe distal venous insufciency, and severe cutaneous 
local lesion.
Assessment
Pretreatment evaluation included a detailed history, 
physical examination, colonoscopy and colorectal phy-
siological assessment: colonic transit study, anorectal 
manometry, rectal sensation, and defecography. 
Constipation was assessed by the Knowles–Eccers-
ley–Scott Symptom scoring system (KESS) [17] at the 
baseline before the first treatment session and after six 
weeks (primary outcome measure). 
The improvement in the patients’ symptoms was also 
assessed by using a two-week diary of the number of 
bowel movements, laxatives, suppositories and enemas 
used before and after six weeks of treatment. The effect 
of treatment on the quality of life was assessed using the 
Gastrointestinal Quality of Life Index (GIQLI) [18]. 
The KESS constipation score was used to rate con-
stipation severity. This score ranges from 0 to 39, with 
0 indicating no symptoms and 39 indicating severe 
constipation [17]. The GIQLI questionnaire consists of 
36 questions that assess the impact of the disease on the 
physical, social, and mental status [18].
The colonic transit time was measured by a validated 
method of performing abdominal radiography 24, 72, 
and possibly 96 hours after the patient had ingested 
radiopaque markers. During this study, the patient was 
instructed not to use laxatives or enemas. The retention 
of markers for more than 72 hours indicated a prolon-
ged transit time [5, 19].
Defecography was performed by a retrograde in-
fusion of the radiopaque contrast and assessing rectal 
configuration and perineal descent while the patient was 
resting, contracting the anal sphincter, and straining to 
defecate [20]. 
Anorectal physiology included rectal sensory testing 
and the rectoanal inhibitory reflex. Rectal sensory tes-
ting was performed by distending the rectum with an 
air-filled balloon. Rectal volumes to distension for the 
first sensation of urge, sensation of the desire to defecate, 
and the maximum tolerated were recorded in milliliters 
[21]. 
Every patient served as his or her own control. The 
study was approved by the Ethics Committee of the 
Vilnius University, and every patient signed a written 
informed consent.
Procedure
TTNS was done with a stimulating Neuro Track TENS 
unit (Verity Medical, UK). Stimulation was done on the 
posterior tibial nerve route using a self-adhesive surface 
stimulation electrode [15, 22]. A negative electrode was 
placed on the ankle skin behind the internal malleolus 
with the positive electrode being placed 10 cm above the 
negative one. The adequate position of the electrode was 
determined by slowly increasing the electric current un-
til sensory and/or motor responses were evident. Typical 
responses included foot sole sensation and/or great toe 
flexion [14]. The appropriate electric current intensity 
level was determined based on the intensity immediately 
under the threshold motor contraction and varied from 
18 to 38 mA. The fixed pulse width of 200 µs and a 
frequency of 20 Hz were applied in a continuous mode 
for 30 min. TTNS was done in the outpatient depar-
tment twice weekly for six weeks (12 procedures) [14].
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Statistical analysis and sample size
A reduction of 5 points in the KESS score was predefi-
ned to be clinically significant. It was estimated that nine 
subjects were required for the study to detect a 5-point 
difference with a 5% significance level and 90% power. 
Continuous variables were checked for the normal 
distribution by the Shapiro–Wilk test. Normally dis-
tributed data were expressed as mean and standard 
deviations, and nonparametric data were expressed as a 
median and the range. Paired tests were used to compare 
data at baseline and after the treatment: a paired t-test 
for parametric and the Wilcoxon signed-ranks test for 
nonparametric variables. The Mann–Whitney U test 
was used to compare unpaired data at baseline and after 
the treatment. A p-value <0.05 was considered statisti-
cally significant. 
Results
Between 2011 and 2013, 49 patients (45 women) with a 
mean age of 52.41 years (SD±17.73) underwent TTNS 
for constipation. All patients completed 12 sessions of 
TTNS in six weeks, filled in bowel diaries, KESS and 
GIQOL questionnaires. The effect was seen in 53.1% 
(26 out of 49) of patients. The overall mean KESS score 
improved significantly with treatment after six weeks 
(from 20.88 ± 5.19 to 15.61 ± 7.19; p < 0.001). In the 
subgroup analysis, 26 patients with a successful treat-
ment had a mean baseline KESS score of 20.58 ± 5.22, 
which improved to a mean score of 11.27 ± 5.78 after 
six weeks of TTNS (p < 0.001) (Figure 1). 
The overall mean two-week stool frequency increased 
from 4.65 ± 2.48 pre-treatment to 7.47 ± 3.51 post-
treatment (p < 0.001). In the effect subgroup, a mean 
of 4.65 ± 2.62 bowel motions per two weeks at baseline 
increased to a mean of 9.69 ± 2.74 after six weeks of 
treatment (p < 0.001). The median number of laxative 
tablets, suppositories and enemas used two weeks before 
treatment was 4 (range, 0–44), and it decreased to a me-
dian of 0 (range, 0–16) after the treatment (p < 0.001). 
There was an improvement in the symptoms associ-
ated with constipation. A significant improvement on 
the subjective rating of the overall severity of abdominal 
pain and bloating was observed with TTNS (Figure 2). 
Figure 1. The KESS score changes before and after the treat-
ment in the effect group
Figure 2. Subjective rating of (a) abdominal pain and (b) 
abdominal bloating at baseline and after six weeks of treatment 
as recorded by the KESS questionnaire
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radiation. Colonic transit normalized in the other two 
patients.
A comparison between success and failure groups 
did not help to define the initial conditions predictive 
of a symptomatic improvement. Both groups had a 
similar age, symptom duration, the KESS score, stool 
frequency, laxative consumption and the GIQLI scores 
at referral. The baseline measures of constipation in 
relation to success or failure of TTNS are shown in 
Table 1. 
The success rate of TTNS was similar in patients 
with a slow and a normal transit time as well as in 
patients with complete and incomplete evacuation in 
defecography. Both groups had similar rectal sensation 
volumes.
The therapy was well tolerated, and no participant 
experienced any adverse event. 
Discussion
The results of this study have shown that TTNS may be 
efcacious in patients with constipation, who have failed 
to respond to maximal conservative treatments. 
To our knowledge, this is the first study evaluating the 
efcacy of TTNS for patients with all forms of consti-
pation, including patients with obstructive defecation. 
The TTNS effect, defined as a reduction in the KESS 
score of 5 points or more, was achieved in more than 
Figure 3. The GIQLI score and subscales before and after six 
weeks of treatment in the effect subgroup (p < 0.05)
Table 1. Baseline measures of constipation in relation to success or failure of TTNS
 All patients  TTNS failure  TTNS success  
Colonic transit study  
Normal, n (%)  39  17 (43.6)  22 (56.4)  
Slow transit, n (%)  10  6 (60)  4 (40)  
Defecography     
Complete evacuation, n (%)  16  7 (44)  9 (56)  
Incomplete evacuation, n (%)  33  16 (48.5)  17 (51.5)  
Rectal sensation threshold (ml),  
median (range)  
First sensation volume,  40 (10–250)  45 (10–250)  40 (10–250)  
Urge volume,  125 (40–350)  120 (40–350)  130 (50–350)  
Maximum volume,  200 (80–500)  225 (80–500)  200 (90–500)  
The overall mean GIQLI score improved from 
92.98 ± 16.06 to 104.76 ± 18.38 (p < 0.001) after six 
weeks (p < 0.001). There was a statistically significant 
improvement in all four GIQLI subscales as compared 
with the baseline level (p < 0.001) (Figure 3). 
A colonic transit study was performed at baseline 
and after six weeks of treatment in case of slow transit 
constipation and TTNS effect. Four out of 10 patients 
with slow colonic transit benefited; however, two of 
them refused to repeat the transit study because of 
197Good results with transcutaneous tibial nerve stimulation for advanced chronic constipation treatment
a half of patients. In the effect group, a considerable 
reduction (of almost 10 points) of the mean KESS 
score was seen after sex weeks of treatment with TTNS. 
A significant increase was seen in stool frequency, and 
a marked decrease was observed in the use of laxatives 
as well as in abdominal pain and bloating. The quality 
of life also increased after the treatment. There was a 
statistically significant improvement in all four GIQLI 
subscales. 
Since different outcome measures and inclusion cri-
teria have been used, a comparison with the results of 
other studies is complicated. The most common outco-
me measured in the studies evaluating the SNS effect 
on constipation was a change in the frequency of defe-
cation [8]. However, the number of defecations is not 
the only sign of constipation. According to the Rome 
III criteria, two or more symptoms must be present for 
six months or more. These include straining at stool, 
passing hard stools, sensation of incomplete emptying, 
sensation of anorectal obstruction, self-digitation and 
defecation frequency of less than three times per week 
[23]. Therefore, the primary outcome in our study was 
a change in the KESS score and not an increase in the 
number of defecations. Currently, neither a standard 
of criteria exists as to which scoring system should be 
used nor there are universally accepted standardized 
inclusion criteria for patients undergoing clinical trials 
for constipation [11, 24]. The KESS score was used in 
this study, because we find it informative and useful 
and use it in our daily practice. Abdominal pain and 
bloating are usually present together with constipation. 
Therefore, we analyzed not only the whole KESS score 
before and after the treatment, but also assessed separate 
particular symptoms. An improvement in the sensation 
of bloating and abdominal pain was seen after the tre-
atment with TTNS. 
Baseline assessments of transit time and incomplete 
evacuation on defecography were not related to the 
outcome of TTNS, suggesting that this treatment 
method may be effective not only for those with cons-
tipation but also for those with evacuation difculties. 
Similar results have been reported from SNS for cons-
tipation studies [11].
The success rate of our six week treatment period can 
be comparable with the percutaneous nerve evaluation 
phase in SNS studies. The success rate of the percuta-
neous nerve evaluation phase for constipation in adults 
in published SNS studies ranged from 42% to 73% [8, 
11]. In our study, the overall effect was seen in 53.1%. In 
2011, Collins et al. published results on 18 patients with 
a slow transit constipation treated with PTNS, using 
needle electrodes. However, a predetermined criterion 
for success was achieved only by a third of participants, 
and colonic transit normalized only in three patients 
(16.6%) [16]. The result in our patients with a slow-
transit constipation was very similar. The effect was seen 
in 40% of patients, although the group was very small 
(only ten patients). Better results were seen in patients 
with obstructive defecation (51.5%) and normal transit 
constipation (56.4%). The reported efcacy of PTNS 
and TTNS in fecal incontinence studies varies from 
54% to 84.3% [14, 15, 22, 25–27]. Nevertheless, these 
are small, uncontrolled trials with different outcome 
measures and heterogeneous patient populations.
In TTNS studies with fecal incontinence patients, 
the stimulation was performed every day by patients 
themselves. Moreover, in some studies the treatment 
course lasted longer – about three months and more 
[22, 26]. Presumably, a better effect might be observed 
after three months of daily stimulation. In order to avoid 
bad patient compliance and to perform the procedure 
in a correct standardized manner, TTNS in our study 
was done in the outpatient department twice a week 
for six weeks. 
As in TTNS studies with fecal incontinence patients 
[15, 22, 26], no adverse effects were seen in our study. 
The procedure was well–tolerated, and the compliance 
of the patients was very good. Whereas, PTNS is a mi-
nimally invasive technique, and mild and rare adverse 
effects have been reported in several studies, which 
include gastrodynia, paraesthesia or numbness and 
bleeding from the needle site [7, 14, 28].
Our study had several limitations. There was no 
control group with sham TTNS, which would allow 
to eliminate the placebo effect. However, blinding in 
such treatment method is difcult, because correct 
electrode placement and current amplitude is confirmed 
by sensory and/or motor response of the foot. There 
is a close association between severe constipation and 
psychological disorders [8]. Thus, the risk of a placebo 
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effect in our study is high, particularly in patients with 
normal colonic transit. PTNS has been shown to be 
significantly more effective than sham stimulation in 
urinary incontinent patients [29]. Effects beyond pla-
cebo suggest findings that PTNS modulates ascending 
spinal pathways [30] and long-term latency somatosen-
sory-evoked potentials [7, 31, 32].
Non-standardized treatment with laxatives was 
another drawback. Patients were asked to continue 
medications and/or rectal irrigation used before the 
study and to alter the dose if needed. In case of TTNS 
efciency, the doses decreased or the medications and/
or irrigations were withdrawn. 
Another limitation was radiological examinations. In 
order to avoid big amounts of radiation, we decided to 
repeat the transit study only in case of a good effect in 
patients with a slow transit constipation. However, some 
patients refused to perform it after the treatment. For 
the same reasons we decided not to repeat proctography.
A lot of questions remain unanswered about the 
TTNS and PTNS effect on defecation disorders. Lar-
ger studies with a better design and control groups are 
needed to rule out the placebo response. It remains 
unclear how long and how often the stimulation should 
be done, and which patients are most likely to benefit 
from the therapy. 
Conclusions
The first results of this study are encouraging. TTNS 
may be a new therapeutic option in patients with cons-
tipation (slow transit constipation as well as obstructive 
defecation) who have failed to respond to the maximal 
conservative treatment. It is a safe, noninvasive, techni-
cally simple procedure which can be easily performed in 
an outpatient setting or at home. 
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